This absence of discrimination of VEGF-A, according to the prognosis of COVID-19 patients, has already been described in small cohort studies, contrary to other endothelial biomarkers, such as angiopoietin-2 or the Intercellular Adhesion Molecule type 1 (ICAM-1) [1,41,42]. This evidence concerns the gene ICAM1 and COVID-19.